Alkermes to Report Third Quarter Financial Results on October 24, 2024
Alkermes plc (Nasdaq: ALKS) has announced it will host a conference call and webcast presentation on Thursday, October 24, 2024, at 8:00 a.m. ET to discuss its third quarter financial results.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Alkermes plc (Nasdaq: ALKS) has announced it will host a conference call and webcast presentation on Thursday, October 24, 2024, at 8:00 a.m. ET to discuss its third quarter financial results. The event will be accessible via the Investors section of Alkermes' website, with a webcast player and accompanying slides available. Participants can join the conference call by dialing +1 877 407 2988 (U.S. callers) or +1 201 389 0923 (international callers).
Alkermes is a global biopharmaceutical company focused on developing innovative medicines in neuroscience. The company has a portfolio of proprietary commercial products for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. Additionally, Alkermes has a pipeline of clinical and preclinical candidates for neurological disorders, including narcolepsy and idiopathic hypersomnia.
Positive
- Alkermes has a diverse portfolio of commercial products for various mental health conditions
- The company has a pipeline of clinical and preclinical candidates for neurological disorders
Negative
- None.
Details
News Market Reaction – ALKS
The recorded move for ALKS in the trading session of this news was -0.21%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for
About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in
Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402
View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-report-third-quarter-financial-results-on-october-24-2024-302279558.html
SOURCE Alkermes plc
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.